Skip to main content
Erschienen in: Neurological Sciences 1/2009

01.05.2009 | Secondary Headaches

Headache induced by the use of combined oral contraceptives

verfasst von: Gianni Allais, Ilaria Castagnoli Gabellari, Gisella Airola, Paola Borgogno, Paola Schiapparelli, Chiara Benedetto

Erschienen in: Neurological Sciences | Sonderheft 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Although combined oral contraceptives (COCs) are a safe and highly effective method of birth control, they may also give rise to problems of clinical tolerability in migraine patients. Indeed, headache is among the most common side effects reported with the use of COCs, frequently leading to their being discontinued. The latest International Classification of Headache Disorders identified at least two entities evidently related to the use of COCs, i.e., exogenous hormone-induced headache and estrogen-withdrawal headache. As to the former, the newest formulations of COCs are generally well tolerated by migraine without aura patients, but can worsen headache in migraine with aura patients. Headache associated with COCs, generally, tends to improve as their use continues. However, although it is not yet clear if there is an association between headache and the composition of COCs (both in the type and amount of hormones), it has been observed that the incidence of headache during COC use seems greater if migraine is associated with menstrual trigger. The estrogen-withdrawal headache is a headache that generally appears within the first 5 days after cessation of estrogen use and resolves within 3 days, even if in some cases it may appear on the sixth or seventh day after pill suspension and lasts more than 3 days.
Literatur
1.
Zurück zum Zitat Loder EW, Buse DC, Golub JR (2005) Headache as a side effect of combination estrogen–progestin oral contraceptives: a systematic review. Am J Obstet Gynecol 193:636–649PubMedCrossRef Loder EW, Buse DC, Golub JR (2005) Headache as a side effect of combination estrogen–progestin oral contraceptives: a systematic review. Am J Obstet Gynecol 193:636–649PubMedCrossRef
2.
Zurück zum Zitat Headache Classification Subcommittee of the International Headache Society (IHS) (2004) The International Classification of Headache Disorders (2nd edition). Cephalalgia 24(Suppl 1):1–151 Headache Classification Subcommittee of the International Headache Society (IHS) (2004) The International Classification of Headache Disorders (2nd edition). Cephalalgia 24(Suppl 1):1–151
3.
Zurück zum Zitat Mueller L (2000) Predictability of exogenous hormone effect in subgroups of migraineurs. Headache 40:189–193PubMedCrossRef Mueller L (2000) Predictability of exogenous hormone effect in subgroups of migraineurs. Headache 40:189–193PubMedCrossRef
4.
Zurück zum Zitat Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Nappi G (2000) Migraine with aura and reproductive life events: a case control study. Cephalalgia 20(8):701–707PubMedCrossRef Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Nappi G (2000) Migraine with aura and reproductive life events: a case control study. Cephalalgia 20(8):701–707PubMedCrossRef
5.
Zurück zum Zitat MacGregor EA, Igarashi H, Wilkinson M (1997) Headaches and hormones: subjective versus objective assessment. Headache Q 8:126–136 MacGregor EA, Igarashi H, Wilkinson M (1997) Headaches and hormones: subjective versus objective assessment. Headache Q 8:126–136
6.
Zurück zum Zitat Cupini LM, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M (1995) Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia 15:140–144PubMedCrossRef Cupini LM, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M (1995) Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia 15:140–144PubMedCrossRef
7.
Zurück zum Zitat Granella F, Sances G, Zanferrari C, Costa A, Martignoni GC (1993) Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 33:385–389PubMedCrossRef Granella F, Sances G, Zanferrari C, Costa A, Martignoni GC (1993) Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 33:385–389PubMedCrossRef
8.
Zurück zum Zitat Massiou H, MacGregor EA (2000) Evolution and treatment of migraine with oral contraceptives. Cephalalgia 20:170–174PubMedCrossRef Massiou H, MacGregor EA (2000) Evolution and treatment of migraine with oral contraceptives. Cephalalgia 20:170–174PubMedCrossRef
9.
Zurück zum Zitat Fotherby K (1992) Clinical experience and pharmacological effects of an oral contraceptive containing 20 micrograms oestrogen. Contraception 46:477–488PubMedCrossRef Fotherby K (1992) Clinical experience and pharmacological effects of an oral contraceptive containing 20 micrograms oestrogen. Contraception 46:477–488PubMedCrossRef
10.
Zurück zum Zitat Gerais AS, Rushwan H (1985) A crossover pill study among Sudanese women. Int J Gynaecol Obstet 23:229–233PubMedCrossRef Gerais AS, Rushwan H (1985) A crossover pill study among Sudanese women. Int J Gynaecol Obstet 23:229–233PubMedCrossRef
11.
Zurück zum Zitat Edelman DA, Kothenbeutel R, Levinski MJ, Kelly SE (1983) Comparative trials of low-dose combined oral contraceptives. J Reprod Med 28:195–200PubMed Edelman DA, Kothenbeutel R, Levinski MJ, Kelly SE (1983) Comparative trials of low-dose combined oral contraceptives. J Reprod Med 28:195–200PubMed
12.
Zurück zum Zitat Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ (2000) Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 95:261–266PubMedCrossRef Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ (2000) Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 95:261–266PubMedCrossRef
13.
Zurück zum Zitat Aegidius K, Zwart JA, Hagen K, Schei B, Stovner LJ (2006) Oral contraceptives and increased headache prevalence. The Head-HUNT study. Neurology 66:349–353PubMedCrossRef Aegidius K, Zwart JA, Hagen K, Schei B, Stovner LJ (2006) Oral contraceptives and increased headache prevalence. The Head-HUNT study. Neurology 66:349–353PubMedCrossRef
14.
Zurück zum Zitat Guillebaud J (1983) The 150/30 formulation. Experience in the United Kingdom. J Reprod Med 28(1 Suppl):66–70PubMed Guillebaud J (1983) The 150/30 formulation. Experience in the United Kingdom. J Reprod Med 28(1 Suppl):66–70PubMed
15.
Zurück zum Zitat Fotherby K (1995) Twelve years of clinical experience with an oral contraceptive containing 30 μg ethinyloestradiol and 150 μg desogestrel. Contraception 51:3–12PubMedCrossRef Fotherby K (1995) Twelve years of clinical experience with an oral contraceptive containing 30 μg ethinyloestradiol and 150 μg desogestrel. Contraception 51:3–12PubMedCrossRef
16.
Zurück zum Zitat Ryan RE (1978) A controlled study of the effect of oral contraceptives on migraine. Headache 17:250–252PubMedCrossRef Ryan RE (1978) A controlled study of the effect of oral contraceptives on migraine. Headache 17:250–252PubMedCrossRef
17.
Zurück zum Zitat Allais G, Bussone G, Airola G, Borgogno P, Castagnoli Gabellari I, De Lorenzo C et al (2008) Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan. Neurol Sci 29(Suppl 1):S186–S190PubMedCrossRef Allais G, Bussone G, Airola G, Borgogno P, Castagnoli Gabellari I, De Lorenzo C et al (2008) Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan. Neurol Sci 29(Suppl 1):S186–S190PubMedCrossRef
Metadaten
Titel
Headache induced by the use of combined oral contraceptives
verfasst von
Gianni Allais
Ilaria Castagnoli Gabellari
Gisella Airola
Paola Borgogno
Paola Schiapparelli
Chiara Benedetto
Publikationsdatum
01.05.2009
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe Sonderheft 1/2009
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-009-0051-9

Weitere Artikel der Sonderheft 1/2009

Neurological Sciences 1/2009 Zur Ausgabe

ANIRCEF – HCNE Joint Meeting

Antimigraine drugs: new frontiers

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.